

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

pKLV2-EF1a-Cas9Bsd-W

RRID:Addgene_68343

Type: Plasmid

Proper Citation

RRID:Addgene_68343

Plasmid Information

URL: <http://www.addgene.org/68343>

Proper Citation: RRID:Addgene_68343

Insert Name: EF1a-Cas9 cassette, WPRE

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:27760321](#)

Vector Backbone Description: Backbone Size:5783; Vector Backbone:pKLV2 lentiviral vector; Vector Types:Lentiviral, CRISPR; Bacterial Resistance:Ampicillin

Plasmid Name: pKLV2-EF1a-Cas9Bsd-W

Record Creation Time: 20220422T222425+0000

Record Last Update: 20260902T050007+0000

Ratings and Alerts

No rating or validation information has been found for pKLV2-EF1a-Cas9Bsd-W.

No alerts have been found for pKLV2-EF1a-Cas9Bsd-W.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 40 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Watterson A, et al. (2026) CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance. *Cell reports. Medicine*, 7(1), 102565.

Zhou J, et al. (2026) CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells. *Leukemia*, 40(3), 511.

Shi X, et al. (2025) Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition. *Nature communications*, 16(1), 2641.

Ruan D, et al. (2025) Establishment of human expanded potential stem cell lines via preimplantation embryo cultivation and somatic cell reprogramming. *Nature protocols*.

Killarney ST, et al. (2025) PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State. *Cancer discovery*, 15(3), 595.

Hsu HE, et al. (2025) Phosphoproteomics of osimertinib-tolerant persister cells reveals targetable kinase-substrate signatures. *Molecular systems biology*, 21(11), 1547.

Lukasiak S, et al. (2025) A benchmark comparison of CRISPRn guide-RNA design algorithms and generation of small single and dual-targeting libraries to boost screening efficiency. *BMC genomics*, 26(1), 198.

Chan PY, et al. (2025) The synthetic lethal interaction between CDS1 and CDS2 is a vulnerability in uveal melanoma and across multiple tumor types. *Nature genetics*, 57(7), 1672.

Huang Y, et al. (2025) Tumor suppressor protein p53 governs human trophoblast lineage development. *Cell reports*, 44(10), 116310.

Zhang W, et al. (2025) METTL3-dependent m6A RNA methylation regulates transposable elements and represses human naïve pluripotency through transposable element-derived enhancers. *Nucleic acids research*, 53(8).

Huang W, et al. (2024) Uncovering the role of TET2-mediated ENPEP activation in trophoblast cell fate determination. *Cellular and molecular life sciences : CMLS*, 81(1), 270.

Pfeifer M, et al. (2024) Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer. *Communications biology*, 7(1), 497.

Klomp JA, et al. (2024) Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. *Science (New York, N.Y.)*, 384(6700), eadk0775.

Sakai M, et al. (2024) Genome-scale CRISPR-Cas9 screen identifies host factors as potential therapeutic targets for SARS-CoV-2 infection. *iScience*, 27(8), 110475.

Petrelli A, et al. (2023) BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. *Cancer research*, 83(10), 1699.

Chen ACH, et al. (2023) Expanded Potential Stem Cells from Human Embryos Have an Open Chromatin Configuration with Enhanced Trophoblast Differentiation Ability. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 10(11), e2204797.

Hermida-Prado F, et al. (2023) Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. *Cancer research*, 83(19), 3284.

Grinkevitch V, et al. (2022) Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists. *Molecular cancer therapeutics*, 21(4), 594.

Liao JQ, et al. (2022) Generation of Monoclonal iPSC Lines with Stable Cas9 Expression and High Cas9 Activity. *Methods in molecular biology* (Clifton, N.J.), 2454, 575.

Gogleva A, et al. (2022) Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer. *Nature communications*, 13(1), 1667.